Veterinary ophthalmology · 2026
Serum Eye Drops for Ocular Surface Disease in Veterinary Ophthalmology: A Translational Review of Human and Veterinary Evidence.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lubián Arenillas Á, Fenollosa-Romero E
Аннотация
BACKGROUND: Serum closely resembles natural tears in composition and contains higher growth factor levels than plasma in humans. Beyond its well-established anticollagenase properties, evidence from human ophthalmology suggests a broader therapeutic potential that may extend to the management of ocular surface diseases in animals.
OBJECTIVES: This review examines the composition, mechanisms, and clinical applications of serum eye drops (SEDs) in human and veterinary ophthalmology, compares serum with plasma, and proposes a protocol for their formulation.
RESULTS: SEDs provide a physiological blend of epitheliotropic factors, including EGF, TGF-β, vitamin A, fibronectin, and protease inhibitors (α2-macroglobulin). Key human indications include dry eye disease and persistent epithelial defects. In veterinary patients, SEDs are primarily used for keratomalacia, with additional potential applications-such as non-healing ulcers, neurotrophic and herpetic keratitis, chemical injuries, toxic keratopathy, and keratoconjunctivitis sicca-though evidence remains limited and largely extrapolated from human studies. Optimal preparation involves 120-min clotting, centrifugation at 3000×g, and optional dilution with saline, BSS, or sodium hyaluronate. Refrigerated storage (4°C) for up to 7 days is supported for canine serum, and at -20°C for 6 months, though stability of some components may vary. Aseptic handling, single-patient use, and refrigeration minimize contamination. SEDs are well tolerated, with few adverse effects reported in humans and none yet in veterinary patients.
CONCLUSIONS: SEDs offer physiologically rational adjunctive therapy for OSD in animals. Although serum and plasma have similar antiprotease activity, serum may promote better epithelial healing. Further veterinary studies are warranted.
OBJECTIVES: This review examines the composition, mechanisms, and clinical applications of serum eye drops (SEDs) in human and veterinary ophthalmology, compares serum with plasma, and proposes a protocol for their formulation.
RESULTS: SEDs provide a physiological blend of epitheliotropic factors, including EGF, TGF-β, vitamin A, fibronectin, and protease inhibitors (α2-macroglobulin). Key human indications include dry eye disease and persistent epithelial defects. In veterinary patients, SEDs are primarily used for keratomalacia, with additional potential applications-such as non-healing ulcers, neurotrophic and herpetic keratitis, chemical injuries, toxic keratopathy, and keratoconjunctivitis sicca-though evidence remains limited and largely extrapolated from human studies. Optimal preparation involves 120-min clotting, centrifugation at 3000×g, and optional dilution with saline, BSS, or sodium hyaluronate. Refrigerated storage (4°C) for up to 7 days is supported for canine serum, and at -20°C for 6 months, though stability of some components may vary. Aseptic handling, single-patient use, and refrigeration minimize contamination. SEDs are well tolerated, with few adverse effects reported in humans and none yet in veterinary patients.
CONCLUSIONS: SEDs offer physiologically rational adjunctive therapy for OSD in animals. Although serum and plasma have similar antiprotease activity, serum may promote better epithelial healing. Further veterinary studies are warranted.